Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : SRNE source : Www.biospace.com save search
Virpax Pharmaceuticals Reports 2023 Year-End Results
Published: 2024-03-26 (Crawled : 20:00) - biospace.com/
VRPX | $3.86 -4.46% -4.66% 6K
|
|
| O: -0.68%
H: 3.17%
C: 2.65%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 11.11%
H: 0.0%
C: -10.0%
virpax pharmaceuticals results
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
Published: 2024-02-27 (Crawled : 13:30) - biospace.com/
VRPX | $3.86 -4.46% -4.66% 6K
|
|
| O: -14.39%
H: 7.35%
C: -0.24%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 7.14%
H: 66.67%
C: -11.0%
virpax pharmaceuticals
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
Published: 2023-11-17 (Crawled : 17:00) - biospace.com/
VRPX | $3.86 -4.46% -4.66% 6K
|
|
| O: 6.92%
H: 0.0%
C: -7.88%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 0.0%
H: 14.29%
C: 3.05%
nasdaq virpax pharmaceuticals
Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company
Published: 2023-09-22 (Crawled : 20:00) - biospace.com/
SCLX | $0.8812 -2.09% -2.13% 2.1M
|
|
| O: 0.0%
H: 2.86%
C: -9.71%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -1.64%
H: 12.33%
C: -0.92%
ORMP | $2.265 2.96% 2.87% 110K
|
Health Technology
|
| O: -3.04%
H: 3.53%
C: 1.96%
company
Sorrento Therapeutics, Inc.'s Bankruptcy Court Extends the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividend
Published: 2023-04-26 (Crawled : 10:00) - biospace.com/
SCLX | $0.8812 -2.09% -2.13% 2.1M
|
|
| O: 3.24%
H: 12.41%
C: 7.56%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.64%
H: 9.68%
C: 7.16%
Scilex Holding Company Announces Financing of up to $25 Million to Enhance Commercialization of Three FDA Approved Non-Opioid Pain Management Products
Published: 2023-03-21 (Crawled : 14:20) - biospace.com/
SCLX | $0.8812 -2.09% -2.13% 2.1M
|
|
| O: -0.38%
H: 6.19%
C: 3.92%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 0.78%
H: 7.24%
C: 5.23%
fda management approved commercialization
Scilex Holding Company announces the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain management
Published: 2023-02-27 (Crawled : 16:00) - biospace.com/
SCLX | $0.8812 -2.09% -2.13% 2.1M
|
|
| O: 1.92%
H: 4.12%
C: -0.59%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.62%
H: 0.0%
C: -29.07%
management commercial
Sorrento Therapeutics has Received FDA Clearance to Initiate Clinical Trials with a Next Generation mRNA (STI-1557) Vaccine Against Omicron SARS-CoV-2 Virus
Published: 2022-12-06 (Crawled : 18:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.68%
H: 0.0%
C: -7.02%
sti-1557 fda clearance trials vaccine mrna virus therapeutics sars-cov-2
Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. with Results To Be Presented at the 2022 American College of Rheumatology Conference
Published: 2022-10-26 (Crawled : 12:00) - biospace.com/
NTRB | $3.91 -3.22% -3.32% 26K
|
Manufacturing
|
| O: 0.24%
H: 10.71%
C: -0.95%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -3.14%
H: 10.39%
C: 3.25%
conference therapeutics study phase 2b
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Published: 2022-09-26 (Crawled : 14:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -0.65%
H: 5.19%
C: -1.95%
treatment osteoarthritis trial therapeutics phase 2
Sorrento Reports Positive Trial Results Utilizing Sofusa Lymphatic Delivery of Etanercept, Achieving Significant Improvements in Rheumatoid Arthritis Disease
Published: 2022-09-15 (Crawled : 15:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -1.93%
H: 6.4%
C: 2.96%
disease trial positive results
Sorrento Therapeutics to Participate in Morgan Stanley 20th Annual Global Healthcare Conference September 12-14
Published: 2022-09-08 (Crawled : 14:00) - biospace.com/
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: -0.38%
H: 2.27%
C: 2.21%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -1.88%
H: 14.35%
C: 13.4%
global conference therapeutics
Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute LBP
Published: 2022-08-31 (Crawled : 08:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 5.15%
H: 2.94%
C: 0.49%
sp-103 ztlido treatment fda designation granted fast track designation
Sorrento Announces Significant Positive Pivotal Trial Results as Assessed by an Independent Review Committee (IRC) With Matured Long-Term (Over Three Years) Follow-Up Data of Abivertinib
Published: 2022-08-23 (Crawled : 16:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 3.95%
H: 3.26%
C: 2.17%
trial review positive results
Scilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement with CH Trading Group LLC
Published: 2022-08-17 (Crawled : 19:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -0.79%
H: 0.4%
C: -15.2%
distribution agreement group
Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ritonavir Booster
Published: 2022-06-03 (Crawled : 15:20) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 8.18%
H: 2.33%
C: -0.58%
sti-1558 covid-19 treatment therapeutics
Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President
Published: 2022-05-31 (Crawled : 12:20) - biospace.com/
ZNTL | $12.97 3.43% 3.32% 1M
|
Health Technology
|
| O: 9.05%
H: 0.0%
C: -1.39%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 8.5%
H: 0.6%
C: -1.2%
Sorrento Therapeutics, Inc. Appoints Former Roche Executive Tammy Reilly to the Board of Directors
Published: 2022-05-18 (Crawled : 16:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -1.91%
H: 4.87%
C: -1.95%
CDNA | $8.32 3.1% 3.0% 500K
|
Health Technology
|
| O: -3.4%
H: 0.0%
C: 0.0%
Sorrento Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib (Fujovee™) to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial)
Published: 2022-05-17 (Crawled : 17:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 4.17%
H: 6.0%
C: 4.67%
fda authorization cancer phase 2 prostate cancer
Scilex, a Sorrento Company, Highlights Safety Data From Phase 1 Trial of SP-104, a Proprietary Low Dose Naltrexone for Fibromyalgia
Published: 2022-05-11 (Crawled : 14:00) - biospace.com/
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -2.11%
H: 0.0%
C: -10.79%
sp-104 fibromyalgia trial phase 1
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.